PROTEON THERAPEUTICS INC (NASDAQ:PRTO) Institutional Investors Q3 2018 Sentiment

Proteon Therapeutics, Inc. (NASDAQ:PRTO) Logo


PROTEON THERAPEUTICS INC (NASDAQ:PRTO) institutional sentiment increased to 2.5 in Q3 2018. Its up 1.64, from 0.86 in 2018Q2. The ratio increased, as 10 hedge funds increased and started new holdings, while 4 decreased and sold stakes in PROTEON THERAPEUTICS INC. The hedge funds in our partner’s database now have: 8.83 million shares, up from 7.28 million shares in 2018Q2. Also, the number of hedge funds holding PROTEON THERAPEUTICS INC in their top 10 holdings was flat from 3 to 3 for the same number . Sold All: 1 Reduced: 3 Increased: 6 New Position: 4.

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. The company has market cap of $47.48 million. It develops vonapanitase, a recombinant human elastase, which is in Phase III clinical trial for patients with chronic kidney disease undergoing surgical creation of a radiocephalic fistula for hemodialysis; has completed a Phase I/II clinical trial in patients undergoing placement of an arteriovenous graft; and is in Phase I clinical trial for the treatment of symptomatic peripheral artery disease. It currently has negative earnings.

The stock decreased 1.20% or $0.03 during the last trading session, reaching $2.47. About 51,106 shares traded or 26.25% up from the average. Proteon Therapeutics, Inc. (NASDAQ:PRTO) has declined 4.86% since January 14, 2018 and is downtrending. It has underperformed by 4.86% the S&P500.

Analysts await Proteon Therapeutics, Inc. (NASDAQ:PRTO) to report earnings on March, 13. They expect $-0.25 EPS, up 19.35 % or $0.06 from last year’s $-0.31 per share. After $-0.25 actual EPS reported by Proteon Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Abingworth Llp holds 2.28% of its portfolio in Proteon Therapeutics, Inc. for 2.02 million shares. Mpm Asset Management Llc owns 983,381 shares or 1.3% of their US portfolio. Moreover, Deer Vii & Co. Ltd. has 0.92% invested in the company for 315,101 shares. The New York-based New Leaf Venture Partners L.L.C. has invested 0.53% in the stock. Ra Capital Management Llc, a Massachusetts-based fund reported 1.34 million shares.

More notable recent Proteon Therapeutics, Inc. (NASDAQ:PRTO) news were published by: which released: “Proteon Therapeutics to Present at Two Upcoming Investor Conferences – GlobeNewswire” on March 06, 2018, also with their article: “Proteon Therapeutics’ stock plummets after failed trial of kidney disease treatment – MarketWatch” published on December 13, 2016, published: “Proteon Therapeutics Receives FDA Breakthrough Therapy Designation for Vonapanitase – GlobeNewswire” on May 10, 2017. More interesting news about Proteon Therapeutics, Inc. (NASDAQ:PRTO) were released by: and their article: “Reader Inquiry: Is Proteon Therapeutics Still A Buy? – Seeking Alpha” published on June 11, 2018 as well as‘s news article titled: “Esterline Technologies Corporation (ESL) Leads 10 Notable Investor Filings –” with publication date: May 03, 2017.

Proteon Therapeutics, Inc. (NASDAQ:PRTO) Institutional Positions Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.